Standing Order
Regeneron Pharmaceuticals, Inc.

Dashboard

Regeneron Pharmaceuticals, Inc.

REGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$94B
Price$920.6952w $483.07 – $973.36
Conviction4/ 5
Revenue (TTM)$16.9B
Revenue growth YoY+18.6%
P/E (trailing)19.4
Gross margin85.8%
Operating margin28.8%
Net margin28.5%
52w price change+87.6%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 18
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 18
    Ownership changeSEC

    SEC Form 4 filing reporting change in beneficial ownership by insider at Regeneron Pharmaceuticals.

  • Nov 18
    Ownership changeSEC

    SEC Form 4 filed reporting change in beneficial ownership.

  • Nov 6
    Ownership changeSEC

    SEC Form 4 filed reporting change in insider beneficial ownership.

  • Nov 5
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 5
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 4
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 4
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 4
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership by insider.

  • Nov 4
    Ownership changeSEC

    SEC Form 4 filing for change in beneficial ownership by insider at REGN.

  • Nov 3
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 3
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership by insider.

  • Nov 3
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership.

  • Oct 30
    Financial resultsSEC

    8-K filing (items 2.02, 9.01) disclosing financial results and exhibits.

  • Oct 15
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Oct 6
    OtherSEC

    8-K filing with items 1.01 (material agreement), 2.02 (financial condition), and 8.01 (other events).

  • Sep 30
    LeadershipSEC

    8-K filing with items 5.02 and 9.01 disclosing officer departure or appointment.

  • Sep 3
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership.

  • Sep 3
    Ownership changeSEC

    SEC Form 4 insider transaction report filed.

  • Aug 21
    Ownership changeSEC

    SEC Form 4 filing for change in beneficial ownership at Regeneron Pharmaceuticals.

Not financial advice — research and opinion only. Disclosures